Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Gedeon Richter raises 2026 profit forecast after strong Vraylar business

Gedeon Richter has raised its forecast for adjusted EBIT in 2026 to double-digit growth at constant exchange rates, supported by a strong Vraylar performance and efficiency measures. For the first half of 2026 the company reported pharma sales of HUF 455.2 billion (+8.7% at constant exchange rates) and adjusted EBIT of HUF 151.8 billion (+21% at constant exchange rates) with a margin of 33.3%. The revenue outlook at constant exchange rates remains in the high single digits; AbbVie also raised its Vraylar sales forecast for 2026 to around USD 4.1 billion. » More on de.investing.com
Gedeon Richter beats expectations, raises 2026 outlook

Gedeon Richter reports pharma sales of HUF 914 billion for 2025 and a currency-adjusted 14% increase in adjusted EBIT, thereby beating consensus estimates and its own forecast. Drivers were strong quarterly results in biosimilars and women’s health and continued growth of Vraylar; generics showed first signs of recovery in Q4. For 2026 the company expects currency-adjusted high single-digit percentage growth in sales and adjusted EBIT, but notes roughly a 5 percentage-point negative impact from exchange rates. Planned R&D spending is around 11% of sales, and restructuring costs of about €100 million are expected through 2030 for ERP and cloud modernization. » More on de.investing.com
Gedeon Richter cuts 2025 forecast after mixed nine-month results

Gedeon Richter has revised its 2025 guidance down after weaker nine-month figures and now expects pharmaceutical sales of around €2.3bn and currency-adjusted adjusted EBIT growth of 8–10% (previously around 10%). In the first nine months the company reported pharmaceutical sales of HUF 668.8bn (€1.67bn), adjusted EBIT of HUF 213.1bn and a margin of 31.9%; however, the third quarter showed declines (sales -1.1%, adjusted EBIT -7.3% and earnings per share down 6.9%). Weaker generics and biologics performance, supply-chain issues and currency effects weighed on results, while the CNS segment and women's health grew strongly. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Gedeon Richter has already paid €1.85 in dividends. The last payout was in June.

Financials

In the last quarter, Gedeon Richter had revenue of €667.74M and net profit of €105.85M

(EUR)	June 2026	YoY
Revenue	667.74M	10.46%
Gross profit	467.61M	10.43%
Net profit	105.85M	18.43%
EBITDA	283.73M	163.25%

Fundamentals

Metric	Value
Market capitalization	€6.48B
Number of shares	182.85M
52-week high/low	€40.61 - €26.21
Dividend yield	5.22%
Dividends TTM	€1.85
Beta	0.34
P/E ratio	10.25
PEG ratio	-2.63
P/B ratio	1.61
P/S ratio	2.54

Company profile

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. The company operates through two segments, Pharmaceuticals, and Wholesale and Retail. It develops and manufactures products in various therapeutic areas, including women's healthcare, cardiovascular, and central nervous system. The company women's healthcare products include contraceptives, endometriosis, fertility, menopause, vaginal infections, and preparations used for the treatment of uterine fibroids. It also offers central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Escapelle and Postinor, an emergency contraceptive pill; Panangin and Folik for pregnancy supplementation; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Groprinosin for antiviral and immunostimulant; Moilec for back and joint pain; Fasconal, a pain relief tablet; Magnezin, a magnesium supplementation; Aflamil, an anti-inflammatory and antirheumatic cream; Oralsept, a sore throat, anti-inflammatory, local anesthetic, and before and after oral surgery spray; Lordestin for allergy; and Curiosin for wound care. Further, it provides financial and accounting, social welfare, portfolio and project management, catering, carriage transportation, engineering, quality control, trading, asset management, and biotechnological services. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.

Name	Gedeon Richter
CEO	Gabor Orban
Headquarters	Budapest, bc Hungary
Website	gedeonrichter.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	10/17/2013
Employees	11,955